Hutchison China MediTech Limited (Chi-Med) is a holding company. The Company is principally engaged in the manufacturing, distribution and sales of Chinese medicine and health products. It operates in three segments: China healthcare, which consists of development, manufacture, distribution and sale of over the counter products, prescription products, and health supplements products; Drug R&D that includes drug discoveries and other pharmaceutical research and development activities, and the provision of research and development services, and Consumer products that include sales of healthcare oriented consumer products and services. During the year ended December 31, 2011, Hutchison MediPharma Limited, a subsidiary of Chi-Med acquired 50% interest of ChuanXinLian R&D Limited. During 2011, Hutchison Whampao Guangzhou Baiyunshan Chinese Medicine Company Limited, a jointly controlled entity of Chi-Med acquired 60% in Guanbao Pharmaceutical Company Limited.